[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL376821A1 - Sposoby zwiększania produkcji polipeptydów - Google Patents

Sposoby zwiększania produkcji polipeptydów

Info

Publication number
PL376821A1
PL376821A1 PL376821A PL37682103A PL376821A1 PL 376821 A1 PL376821 A1 PL 376821A1 PL 376821 A PL376821 A PL 376821A PL 37682103 A PL37682103 A PL 37682103A PL 376821 A1 PL376821 A1 PL 376821A1
Authority
PL
Poland
Prior art keywords
methods
polypeptide production
increasing polypeptide
increasing
production
Prior art date
Application number
PL376821A
Other languages
English (en)
Inventor
Ness Kirk P. van
Michael T. Trentalange
Bradley D. Dell
Jeffrey T. McGrew
Original Assignee
Immunex Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corporation filed Critical Immunex Corporation
Publication of PL376821A1 publication Critical patent/PL376821A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL376821A 2002-03-27 2003-03-27 Sposoby zwiększania produkcji polipeptydów PL376821A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36824802P 2002-03-27 2002-03-27
US36824602P 2002-03-27 2002-03-27

Publications (1)

Publication Number Publication Date
PL376821A1 true PL376821A1 (pl) 2006-01-09

Family

ID=28678222

Family Applications (1)

Application Number Title Priority Date Filing Date
PL376821A PL376821A1 (pl) 2002-03-27 2003-03-27 Sposoby zwiększania produkcji polipeptydów

Country Status (9)

Country Link
US (2) US6872549B2 (pl)
EP (1) EP1497444B1 (pl)
JP (3) JP2005521401A (pl)
AU (1) AU2003220529B2 (pl)
CA (1) CA2480121C (pl)
ES (1) ES2557741T3 (pl)
MX (1) MXPA04009381A (pl)
PL (1) PL376821A1 (pl)
WO (1) WO2003083066A2 (pl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050005310A1 (en) * 1999-07-12 2005-01-06 Genentech, Inc. Expression vectors and methods
MXPA04009381A (es) * 2002-03-27 2005-01-25 Immunex Corp Metodos para incrementar la produccion de polipeptidos.
EP1567658A2 (en) * 2002-11-14 2005-08-31 Genentech, Inc. Intron fusion construct and method of using for selecting high-expressing production cell lines
US20040265964A1 (en) * 2003-04-25 2004-12-30 Martin Allen Inducers of recombinant protein expression
US20050112194A1 (en) * 2003-08-21 2005-05-26 Duchesnay Inc. Micronutrient supplement dispensing package
WO2005018652A1 (en) * 2003-08-21 2005-03-03 Duchesnay Inc. Micronutrient supplement
EP1697414A2 (en) * 2003-12-23 2006-09-06 Applied Research Systems ARS Holding N.V. Process for the production of tumor necrosis factor-binding proteins
US20080311078A1 (en) 2005-06-14 2008-12-18 Gokarn Yatin R Self-Buffering Protein Formulations
WO2007049567A1 (ja) * 2005-10-24 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. 物質の製造方法
BRPI0622251A2 (pt) 2005-12-20 2011-07-19 Bristol-Myers Squibb Company método para obtenção de uma composição compreendendo uma população isolada de moléculas de ctla4-ig de um meio de cultura lìquido e para isolamento de uma composição compreendendo moléculas de ctla4-ig e composição
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
EP3438131B1 (en) * 2006-02-10 2022-03-16 Life Technologies Corporation Oligosaccharide modification and labeling of proteins
WO2008082436A2 (en) * 2006-08-14 2008-07-10 Biocontrol Systems, Inc. Method for detecting pathogens
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
AU2007294731B2 (en) 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
US8357514B2 (en) * 2007-03-28 2013-01-22 Medarex, Inc. Methods of gene amplification and expression
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US20090023186A1 (en) * 2007-07-22 2009-01-22 Excellgene Sa Use of valproic acid for enhancing production of recombinant proteins in mammalian cells
JP2011512877A (ja) * 2008-03-12 2011-04-28 ワイス・エルエルシー 組換えタンパク質の大スケール産生に適した細胞を同定する方法
IN2012DN05169A (pl) * 2009-12-02 2015-10-23 Acceleron Pharma Inc
CN103080221B (zh) 2010-09-30 2015-11-25 大金工业株式会社 防熔滴剂以及树脂组合物
JP6001456B2 (ja) * 2010-12-28 2016-10-05 中外製薬株式会社 動物細胞の培養方法
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2012170938A1 (en) 2011-06-08 2012-12-13 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life
CA2952347A1 (en) 2011-07-01 2013-01-10 Amgen Inc. Mammalian cell culture
EP2653548A1 (de) 2012-04-17 2013-10-23 Greenovation Biotech GmbH Verfahren zur Erhöhung der Sekretion rekombinanter Proteine
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP2970888A4 (en) * 2013-03-15 2017-04-12 Theocorp Holding Co., LLC Theobromine compositions useful for increasing fetal weight gain and enhancing bone properties
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
AU2017345490B2 (en) 2016-10-21 2022-07-07 Amgen Inc. Pharmaceutical formulations and methods of making the same
KR102190790B1 (ko) * 2018-10-19 2020-12-15 주식회사 프로젠 변형된 egf 단백질의 생산 방법
EP3702365A4 (en) * 2017-10-23 2021-11-10 Progen Co., Ltd. MODIFIED EGF PROTEIN, ITS PRODUCTION PROCESS AND ITS USE
WO2022140389A1 (en) 2020-12-22 2022-06-30 Amgen Inc. Cell culture method

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3824286A (en) * 1970-07-07 1974-07-16 Lever Brothers Ltd Preparation of polyacetylalkylene diamines
EP0005476B1 (de) * 1978-05-17 1981-12-30 Dr. Karl Thomae GmbH Verfahren zur Herstellung von Humaninterferon
US4301249A (en) * 1980-07-23 1981-11-17 Merck & Co., Inc. High titer production of hepatitis A virus
US4357422A (en) * 1980-08-14 1982-11-02 Massachusetts Institute Of Technology Method of enhancing interferon production
US4416986A (en) * 1981-01-16 1983-11-22 Merck & Co., Inc. Methods of producing HBsAg
US4473647A (en) * 1981-02-27 1984-09-25 Amf Inc. Tissue culture medium
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4992472A (en) * 1987-06-16 1991-02-12 The United States Of America As Represented By The Department Of Health And Human Services Chemical differentiating agents
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5330744A (en) * 1988-11-14 1994-07-19 Sloan-Kettering Institute For Cancer Research Method for increasing sensitivity to chemically induced terminal differentiation
US5055608A (en) * 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
ZA899421B (en) 1988-12-14 1990-09-26 Merrell Dow Pharma Method of potentiating natural killer cell activity
IL94611A (en) * 1989-06-05 1994-12-29 Organogenesis Inc Medium for cell cultures containing insulin or growth factor similar to insulin, transferrin or iron ion, triiodothyronine or thyroxine and method of use
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP0417563B1 (de) 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
CA2146559A1 (en) 1992-10-23 1994-05-11 Melanie K. Spriggs Methods of preparing soluble, oligomeric proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US20010010922A1 (en) 1994-06-09 2001-08-02 Riccardo Dalla-Favera Cloning and uses of the genetic locus bcl-6
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
DK1666591T3 (da) 1995-06-29 2011-05-23 Immunex Corp Cytokin der inducerer apoptose
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
WO1998028010A2 (en) 1996-12-24 1998-07-02 Hyal Pharmaceutical Corporation Use of moieties for binding to hyaluronan and icam-1
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU1663599A (en) 1997-12-19 1999-07-12 Novo Nordisk A/S Method for producing heterologous proteins in eukaryotic cells on an industrial scale using nucleotide-manipulating agents
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
WO2000020576A2 (en) 1998-10-02 2000-04-13 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services, The National Institutes Of Health Methods and compositions for inducing differentiation and apotosis in cells that overexpess the notch protein
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6506598B1 (en) * 1999-04-26 2003-01-14 Genentech, Inc. Cell culture process
DK1222298T3 (da) 1999-10-13 2006-04-10 Immunex Corp Vektorer og fremgangsmåder til rekombinant proteinekspression
WO2001036637A1 (en) 1999-11-17 2001-05-25 Immunex Corporation Receptor activator of nf-kappa b
WO2001083525A2 (en) 2000-05-03 2001-11-08 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
MXPA04009381A (es) * 2002-03-27 2005-01-25 Immunex Corp Metodos para incrementar la produccion de polipeptidos.

Also Published As

Publication number Publication date
US20050233415A1 (en) 2005-10-20
JP2008167760A (ja) 2008-07-24
US7452695B2 (en) 2008-11-18
MXPA04009381A (es) 2005-01-25
AU2003220529A1 (en) 2003-10-13
JP4414466B2 (ja) 2010-02-10
US20030211579A1 (en) 2003-11-13
ES2557741T3 (es) 2016-01-28
EP1497444A2 (en) 2005-01-19
CA2480121A1 (en) 2003-10-09
JP2005521401A (ja) 2005-07-21
AU2003220529B2 (en) 2006-09-07
EP1497444A4 (en) 2006-08-30
EP1497444B1 (en) 2015-11-04
JP2009082138A (ja) 2009-04-23
US6872549B2 (en) 2005-03-29
WO2003083066A3 (en) 2004-02-26
WO2003083066A2 (en) 2003-10-09
JP4414472B2 (ja) 2010-02-10
CA2480121C (en) 2012-02-28

Similar Documents

Publication Publication Date Title
PL376821A1 (pl) Sposoby zwiększania produkcji polipeptydów
HUS1500016I1 (hu) Tiacumicin elõállítása
AU2003283174A8 (en) Method for protein production
AU2003206684A8 (en) Plant polypeptide production
PL377943A1 (pl) Sposób wytwarzania benzofenonów
IL162780A0 (en) Method for producing modified peptide
GB0201505D0 (en) Process
EP1539982A4 (en) glutathione
EP1614695A4 (en) POLYPEPTIDE
PL372214A1 (pl) Nowy sposób
GB0218977D0 (en) Polypeptide
GB0201378D0 (en) Process
HK1082000A1 (en) Method for producing cephalexin
GB0202563D0 (en) Process
GB0223193D0 (en) Polypeptide
GB0229967D0 (en) Protein production
GB0218030D0 (en) Multi-submit protein production system
GB0208925D0 (en) Polypeptide
PL374000A1 (pl) Ulepszony sposób wytwarzania hydroksyazapironów
GB0229476D0 (en) Novel process
GB0206655D0 (en) Novel process
EP1477559A4 (en) NEW POLYPEPTIDE
GB0202221D0 (en) Novel polypeptide
PL377523A1 (pl) Sposób wytwarzania zrekombinowanej heterokarpiny
GB0222616D0 (en) Novel method

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)